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The traditional cardiac regenerative paradigm using
non-modified adult stem cells with various routes of
delivery into the myocardial target has thus far yielded
unconvincing clinical outcomes. Besides factors related
to heterogeneity in trial methodology, inter-patient
variability and the rare incidence of adult stem cells
with intrinsic repair potency underscore the importance
of further optimization and standardization of
regenerative platforms. Cardiac tissue engineering
seizing upon the advances of cellular, molecular,
and biomaterial development is shaping the next
generation of the regenerative paradigm and thereby
fostering disruptive curative treatments in heart failure.pericardial bioscaffold preparation implanted early
after experimental myocardial infarction. Detailed im-Introduction
In a recent article in Stem Cell Research & Therapy,
Gálvez-Montón et al. [1] provide new evidence that neu-
rovascular integration of acellular pericardial-derived scaf-
fold may induce cardiac repair. Ischemia-induced myocyte
loss is associated with degradation of the extracellular
matrix and induction of replacement fibrosis as the pri-
mary trigger of adverse ventricular remodeling and heart
failure progression. Cell-based regenerative interventions
are under investigation as an adjunct to current standards
of care in two main settings. If employed acutely after
myocardial infarction, cell-based therapy is thought to fa-
cilitate myocardial recovery through a cardioprotective
pathway. Conversely, in the setting of established cardiac
dysfunction, the restorative impact of cell-based therapy
aborts pathological remodeling and contributes to the
restoration of healthy tissue. Although various clinical tri-
als have demonstrated the safety and feasibility of these
approaches, varied signals of benefits between trials have* Correspondence: jozef.bartunek@olvz-aalst.be
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Cardiac tissue engineering and biomaterial scaffolds
offer an alternative strategy to regenerate damaged
myocardium. They are applied as a patch or as an in-
jection to overcome the hostile ischemic milieu either
to facilitate the transplanted cell survival or to pro-
mote endogenous repair by facilitating electromechan-
ical coupling and neovasculogenesis [2, 3]. This is key
in ensuring the transport of nutrients and functional
integration of the scaffold. Using a cell-free pericardial
scaffold, the present study provides biological proof of
concept for such an approach in a large animal model
of acute myocardial infarction [1]. It demonstrates
neovascularization and nerve formation in a cell-free
munohistochemistry and electron microscopy analysis
demonstrate the functional neovascularization without
adjunctive growth factor stimulation. Neovasculariza-
tion with intraluminal erythrocytes has been observed
across the entire thickness of the scaffold away from
the host myocardium. Furthermore, authors report de
novo nerve sprouting [1]. At the ultrastructural level,
these neuronal cells contain structural organelles con-
sistent with the differentiated neuronal afferent cells.
The underlying mechanism and signaling were not elu-
cidated here. However, in contrast to synthetic scaf-
folds, the porous structure of prepared pericardium
features preserved biological tunnels, which in the set-
ting of hypoxia likely provide the necessary cues for the
host progenitor cells facilitating their migration and
scaffold integration [4]. Because the scaffold delivery
here was performed early after the myocardial infarc-
tion where abundant inflammatory and reparative sig-
nals exist, it remains unclear whether a similar degree
of neurovascular integration would occur in chronic
myocardial infarction. In addition, the lack of a control
group prevents the broader translation of infarct sizele is distributed under the terms of the Creative Commons Attribution 4.0
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Aside from the inherent limitations of this biological
proof-of-concept experiment, there are several implica-
tions for the framework of cardiac regeneration. The
traditional cardiac regenerative paradigm using non-
modified adult stem cells with various routes of deliv-
ery into the myocardial target has thus far yielded
unconvincing clinical outcomes [5]. Factors related to
heterogeneity in trial methodology, inter-patient vari-
ability, and the rare incidence of adult stem cells with
intrinsic repair potency underscore the importance of
further optimization and standardization of regenera-
tive platforms [5]. Optimization efforts span all levels
of the regenerative paradigm (Table 1). Moving beyond
heterogenous biologics such as bone marrow mono-
nuclear cells, ongoing clinical trials have employed
cell-sorting strategies to boost the endogenous regen-
erative potential. This next-generation strategy either
purifies unique populations of autologous or allogeneic
progenitors [6] or achieves anatomical matching with
propagation of resident cardiac stem cells [7]. Further-
more, identification of signals that govern cardiogenic
specification facilitated the development of cardiopoi-
esis technology used to boost the regenerative impact
of patient-derived stem cells [8].
Use of acellular approaches to achieve cardiac regener-
ation has evolved out of stem cell science but aims to
achieve regeneration without the cell-to-cell variability
and high manufacturing costs associated with cell therapy.
Here, delivery of restorative exogenous signals through
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Tissue engineering Bioscaffolds Facilitate cell surv
endogenous repaintrinsic repair function of the heart by modulating the
interplay between reactive inflammatory response and
stem cell recruitment into the ischemic tissue. In this re-
gard, manipulation of the myocardial microenvironmental
appears to boost the stem cell recruitment into the peri-
vascular niche and enhance the efficacy of autologous
stem cell delivery [9].
Beyond cell-based or cell-free strategies that boost the
endogenous myocardial response, procedural optimization
to augment the retention of biologics relies on the devel-
opment of novel delivery devices or methods to optimize
procedural guidance [10]. Alternatively, engineered bioma-
terial scaffolds may help to overcome challenges currently
attributed to cell retention or host tissue niche modifica-
tion [2]. The present study provides a biological proof of
concept that pericardial scaffolds can integrate with host
tissue in the setting of acute myocardial infarction, creating
neurovascular networks in the epicardial space. Although
implementation of this particular approach early after in-
farction is clinically impractical, integration in chronic
models of heart failure may provide a novel approach to
regeneration. The observations in this study pave the road
for further studies to explore the functional effects of bios-
caffold alone or in combination with various cell types.Conclusion
Cardiac tissue engineering seizing upon the advances of
cellular, molecular, and biomaterial development is shap-
ing the next generation of the regenerative paradigm and





• Synergistic use of MSCs and cardiac progenitor cells
(CPCs) is currently under investigation
• Strong signals of benefit with EPCs
l
• Two phase II trials completed





• Early signals of efficacy
• This paradigm is under phase III investigation




Paracrine influence of progenitors achieves enhanced




Significant advances in tissue processing and three-
dimensional printing have paved the way for cell-free
approaches for cardiac regeneration
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